Skip to content
News

Semaglutide News: November 2026 Updates (EVOKE Results, Foundayo in Europe, CagriSema Wait)

5 min readLast updated By Jeremy H., GLP-1 Nutrition Researcher
Semaglutide News: November 2026 Updates (EVOKE Results, Foundayo in Europe, CagriSema Wait)
§

This article may contain affiliate links. If you click and make a purchase, we may earn a commission at no extra cost to you. Full disclosure policy

Last updated: November 16, 2026. This page is updated monthly, newest first. Each item below is dated and sourced; older items are kept under "Earlier in 2026" so the page does not decay into a stale-content signal.

November 2026

1. EVOKE and EVOKE+ Alzheimer's Trials: Negative Results

Novo Nordisk's EVOKE and EVOKE+ phase 3 trials tested oral semaglutide in early Alzheimer's disease — 3,808 participants over 104 weeks. The trials were completed in 2026 and the results were negative: no difference from placebo on the CDR-SB cognitive scale. The findings were published in The Lancet in 2026, and the extension study was discontinued.

What this means: the idea that a GLP-1 could slow Alzheimer's had real trial data behind it, and the trials answered the question — for oral semaglutide in early Alzheimer's, the answer was no. It does not change semaglutide's approved uses for diabetes and weight management. See our GLP-1 and brain health guide for the full trial-status table.

2. Foundayo Earns a Positive CHMP Opinion in Europe (October 15, 2026)

The European Medicines Agency's CHMP issued a positive opinion for Foundayo (orforglipron) on October 15, 2026 — the step before a European marketing authorization. Foundayo is a different drug from semaglutide (an oral small-molecule GLP-1, not a peptide), and its main edge over the Wegovy pill is that it has no food or water restrictions. Read our Foundayo EMA opinion article.

3. CagriSema: Still Awaiting an FDA Decision

As of November 2026, CagriSema (semaglutide + cagrilintide) remains under FDA review, with a decision expected in late 2026 or early 2027. Nothing has changed since the May update below — no approval, no rejection, no new date. If approved, launch would likely follow in 2027.

Earlier in 2026

The semaglutide landscape shifted significantly in May 2026. Ozempic oral tablets are now at pharmacies, Wegovy HD is available, and the pipeline behind them keeps growing. Here's what happened.

Ozempic Oral Tablets Now at US Pharmacies (May 4)

Ozempic oral tablets launched at US pharmacies on May 4, 2026. This is a milestone: the first oral peptide GLP-1 receptor agonist with demonstrated MACE (Major Adverse Cardiovascular Events) reduction.

Available doses:

  • 1.5 mg — Starting dose
  • 4 mg — Maintenance dose
  • 9 mg — Higher maintenance dose

Like Rybelsus, the tablets require taking on an empty stomach with no more than 4 oz of water, then waiting 30 minutes before eating or drinking. If you want an oral GLP-1 without food restrictions, Foundayo is an alternative — but it uses a different drug (orforglipron), not semaglutide.

For the full breakdown of oral GLP-1 options, see our GLP-1 Pill Guide and Wegovy Pill vs Injection.

Wegovy HD (7.2 mg) — Approved March 2026

The FDA approved Wegovy HD (semaglutide 7.2 mg) on March 19, 2026, after a 54-day fast-track review. It's triple the standard 2.4 mg maintenance dose.

Key data:

  • 20.7% average weight loss at 72 weeks in clinical trials
  • Not a starting dose — for patients already on 2.4 mg Wegovy for at least 4 weeks
  • Now available at pharmacies as of April 2026

Wegovy HD is for people who plateaued on the standard dose and need more. See our full Wegovy HD Guide for eligibility, dosing, and side effects.

Wegovy Pill (Oral Semaglutide 25 mg) — Approved December 2025

Separate from the Ozempic tablet above, the Wegovy pill (oral semaglutide 25 mg) is a distinct weight-management product that the FDA approved in December 2025 and Novo Nordisk launched at US pharmacies in January 2026. In the OASIS 4 trial, adherent patients lost an average of 16.6% of body weight. A 50 mg dose was studied in the earlier OASIS 1 trial (~15% weight loss) but remains investigational and is not FDA-approved.

This gives patients another needle-free option beyond the 9 mg ceiling of the diabetes-indicated Ozempic tablet. See our Wegovy Pill Doses guide for the full titration schedule.

GLP-1 medication news, in plain English

New approvals, pens, pills, prices and label changes across GLP-1 medications. One free email a week.

CagriSema — FDA Under Review (May 2026 Status)

CagriSema combines semaglutide with cagrilintide (an amylin analog) for dual appetite suppression. Phase 3 REDEFINE 1 trial results showed 20.4% average weight loss over 68 weeks — beating semaglutide alone (13.7%).

Important: CagriSema is not approved. Novo Nordisk submitted its FDA application in late 2025, and a decision is expected in late 2026 or early 2027. If approved, launch would likely follow in 2027.

Read the full breakdown in our CagriSema guide.

Generic Timeline: Still Years Away (May 2026)

Semaglutide does not yet have a generic version in the United States. Key dates:

Brand Earliest Expected Generic
Ozempic 2031
Wegovy 2032

Patent litigation could shift these dates, but for now, no generic semaglutide is coming soon. The compounded semaglutide market continues to evolve, but compounded drugs are not FDA-approved and carry quality risks. For ongoing product liability cases, see our Ozempic lawsuits tracker.

See our Semaglutide Generic Availability guide for the full picture.

Novo Nordisk Shortage Status (May 2026)

Supply is improving as of May 2026. Key points:

  • Wegovy 2.4 mg is now more widely available
  • Ozempic 1 mg and 2 mg still face periodic shortages
  • Novo Nordisk and Eli Lilly have expanded manufacturing capacity
  • Most doses are expected to be consistently available by late 2026

For current availability and what to do if your medication is out of stock, see our GLP-1 Shortages guide.

Mounjaro Receives a Cardiovascular Indication (August 28, 2026)

The FDA approved Mounjaro (tirzepatide) on August 28, 2026 to lower the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with type 2 diabetes who are at high risk for these events.

SURPASS-CVOT found Mounjaro noninferior to Trulicity for MACE-3, but it did not establish superiority. See our Mounjaro cardiovascular approval analysis for what the 8% relative-hazard figure means. For prices across GLP-1s, see our GLP-1 Cost Comparison guide.

The Bottom Line

November 2026: oral semaglutide's Alzheimer's trials came back negative, Foundayo moved a step closer in Europe, and CagriSema is still waiting on the FDA. The May launches — oral Ozempic tablets, Wegovy HD, the Wegovy pill — are all now established options. Generics remain years away. Work with your doctor to find the right option for you, and stay informed through reliable sources.

This article is for information only. Always talk to your doctor for personalized medical advice. For FDA updates, visit fda.gov.

Helpful Products for GLP-1 Treatment

Managing your GLP-1 medication is easier with the right tools:

GLPSpot may earn from qualifying purchases.

Related Reading

GLP-1 medication news, in plain English

New approvals, pens, pills, prices and label changes across GLP-1 medications. One free email a week.

We respect your privacy. Unsubscribe anytime.

Next up

A few related reads to keep your momentum.

GLP-1 Pills: FDA-Approved Oral Weight Loss Options
Medications
Apr 2, 2026
GLP-1 Pills: FDA-Approved Oral Weight Loss Options
Oral GLP-1 options are growing. Here's what's FDA-approved and how pills compare to injections.
Wegovy HD (7.2 mg): Results, Side Effects, Cost, and Who It's For (May 2026 Update)
Medications
Apr 3, 2026
Wegovy HD (7.2 mg): Results, Side Effects, Cost, and Who It's For (May 2026 Update)
Wegovy HD (7.2 mg) delivers 20.7% average weight loss for patients who plateau on standard Wegovy. Updated with real-world availability, cost, savings cards, and how it compares to Zepbound and Mounjaro.
Wegovy Pill vs Injection: How They Compare in 2026
Guides
Mar 29, 2026
Wegovy Pill vs Injection: How They Compare in 2026
Oral semaglutide (the "Wegovy pill") and injectable Wegovy are both semaglutide, but the numbers only tell part of the story. Here is how they compare on trial data, dosing, cost, side effects, and convenience — including how preliminary conference data on Foundayo should be read with caution.
CagriSema: What It Is, Trial Results, and When It's Coming
Medications
Apr 5, 2026
CagriSema: What It Is, Trial Results, and When It's Coming
CagriSema combines semaglutide with cagrilintide for stronger weight loss. Phase 3 REDEFINE shows 20.4% weight loss; REIMAGINE-2 shows 14.2% vs Ozempic 10.2% head-to-head in T2D. FDA decision expected late 2026 or early 2027.
Semaglutide Generic: When Will It Be Available and What to Know
Medications
Apr 10, 2026
Semaglutide Generic: When Will It Be Available and What to Know
Wondering when semaglutide (Ozempic, Wegovy) will be available as a generic? Learn about patent status, expected generic dates, and what this means for cost.
GLP-1 Shortages & Backorders: Ozempic, Wegovy & Mounjaro Availability (May 2026)
News
Apr 2, 2026
GLP-1 Shortages & Backorders: Ozempic, Wegovy & Mounjaro Availability (May 2026)
Ozempic, Wegovy or Mounjaro out of stock or on backorder? Learn what to ask your pharmacist, where to check availability, and what alternatives to discuss with your doctor.
GLP-1 Cost Comparison 2026: What You'll Actually Pay
Cost
Apr 3, 2026
GLP-1 Cost Comparison 2026: What You'll Actually Pay
Compare real GLP-1 costs in 2026, with or without insurance — list prices, copays, savings cards, LillyDirect self-pay, generics, Medicare Bridge, Foundayo pricing, and a budgeting framework so you know your true monthly spend.
Orforglipron (Foundayo): Side Effects, Price, and Doses
Medications
Apr 23, 2026
Orforglipron (Foundayo): Side Effects, Price, and Doses
Foundayo (orforglipron) is an FDA-approved daily pill for chronic weight management in eligible adults. Review its indication, FDA-label dose schedule, clinical-trial results, safety information, and current access details.

Related articles

Written by
J
Jeremy H.
GLP-1 Nutrition Researcher

Nutrition researcher and founder of The GLPSpot. Jeremy built this site after watching friends and family struggle with the nutritional challenges of reduced appetite on GLP-1 medications — loss of muscle mass, dehydration, and nutrient deficiencies.

Published:
Medical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.